检索结果-南通市图书馆

Liver Research 2021年第4期5卷 217-223页

作者： jiongshan zhang Yue Li Gemin Xiao Yongwei Li Heping Xie Yan Chen Department of Traditional Chinese Medicine The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina

Background:Non-alcoholic fatty liver disease(NAFLD)is a frequently occurring clinical disease,which could be treated by traditional Chinese medicine.However,the effects and mechanisms of xiao-zhi-fang(XZF)alone or in combination with fructooligosaccharides(FOS)on NAFLD remains unclear.Methods:This study established the NAFLD mouse model by feeding with a high-fat diet and by administering with XZF and/or FOS.Moreover,the fat content in the liver tissues was evaluated by oil red O and hematoxylin and eosin staining,and the liver function indices were examined using a biochemical analyzer.Changes in the intestinal flora were monitored using 16S rRNA gene sequencing.The results of the current study showed that the alanine aminotransferase,aspartate aminotransferase,total triglyc-eride,total cholesterol levels,and the amount of lipid accumulation were markedly elevated in NAFLD mice.Results:XZF alone or in combination with FOS significantly reduced lipid accumulation in the liver and blood lipid levels in NAFLD mice.Moreover,XZF alone or in combination with FOS notably altered the intestinal flora structure in NAFLD mice.Consequently,17 operational taxonomic units were decreased and nine were increased in the XZF and/or FOS groups.Conclusions:FOS may accelerate the intestinal microecological balance in NAFLD mice after treatment with XZF by promoting intestinal flora growth,thereby enhancing the therapeutic effect of XZF on NAFLD.

关键词： Fructooligosaccharides(FOS) High-fat diet(HFD) Intestinal flora Non-alcoholic fatty liver disease(NAFLD) Xiao-zhi-fang(XZF)

Correlation between Traditional Chinese Medicine symptom patterns and serum concentration of zinc,iron,copper and magnesium in patients with hepatitis B and associated liver cirrhosis

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Traditional Chinese Medicine 2015年第5期35卷 546-550页

作者： Teng Lichun zhang jiongshan Dai Min Wang Fenglin Yang Hongzhi Department of Traditional Chinese Medicine the Third Affiliated Hospital of Sun Yat-Sen University

OBJECTIVE:To investigate the correlation between the patterns of Traditional Chinese Medicine(TCM)syndromes and the serum concentration of zinc,iron,copper and magnesium of patients with chronic hepatitis B(CHB) and hepatitis B virus(HBV)-induced liver cirrhosis.METHODS:A total of 86 patients were included in the study between March 1,2009 and January 1,2010.All were diagnosed with CHB or HBV-induced liver cirrhosis according to the diagnosis standard of the Chinese Medical Association.Fasting serum concentrations of zinc,iron,copper and magnesium were measured.Patients were classified into different patterns of TCM symptoms according to TCM theory and clinical experience.RESULTS:In the HBV-induced liver cirrhosis group,the mean zinc concentration in patients with the TCM pattern of stagnation of fluid-Dampness was lower than that in patients with obstruction of collaterals by Blood stasis(P < 0.034).In the CHB group,the mean magnesium concentration in patients with toxic Heat flourishing was significantly lower than that in those with Damp-Heat in the Liver and Gallbladder,and those with Liver depression and Spleen deficiency(P < 0.021).The concentrations of iron and copper showed little difference among the different TCM symptom patterns.CONCLUSION:The serum zinc and magnesium concentrations correlated with certain TCM patterns of symptoms in patients with HBV-induced liver cirrhosis and CHB.It may be helpful to interpret the pathogenic change in the TCM symptom patterns in liver cirrhosis and CHB,and also to conduct clinical treatment of the diseases based on identified TCM patterns.

关键词：乙型肝炎病毒中医理论肝硬化镁含量血清锌患者证型慢性乙型肝炎

肝复乐胶囊联合射频消融术治疗原发性肝癌的临床疗效

在线全文

学校读者我要写书评

暂无评论

新医学 2021年第5期52卷 339-342页

作者：向旭邹增城张炯善中山大学附属第三医院中医科广州510630

目的探讨肝复乐胶囊联合射频消融术治疗原发性肝癌患者的临床疗效。方法回顾性分析89例原发性肝癌的病例资料,根据治疗方式分为观察组60例与对照组29例。对照组采用射频消融术治疗,观察组患者在射频消融术治疗基础上加服肝复乐胶囊(3 g/... 详细信息

目的探讨肝复乐胶囊联合射频消融术治疗原发性肝癌患者的临床疗效。方法回顾性分析89例原发性肝癌的病例资料,根据治疗方式分为观察组60例与对照组29例。对照组采用射频消融术治疗,观察组患者在射频消融术治疗基础上加服肝复乐胶囊(3 g/次,每日3次,连续服用4周)。比较2组治疗前后甲胎蛋白、白蛋白、生活质量以及中医证候改善情况。结果治疗后,观察组甲胎蛋白阳性率为8.3%,低于对照组的66.7%(χ^(2)=26.568,P<0.001);治疗后观察组血清白蛋白水平高于对照组,2组比较差异有统计学意义(Z=-2.119,P=0.034);观察组生活质量评分提高率为80.0%,对照组为55.2%,观察组较对照组治疗前后生活质量评分提高率更高(P<0.05)。观察组中医证候评分改善情况总有效率为68.3%;对照组总有效率为27.6%,根据总有效数值以及总有效率分析,观察组较优。结论肝复乐胶囊联合射频消融术治疗原发性肝癌的患者有更加良好的临床治疗意义,可以在一定程度上增强患者的康复能力,提升生活质量。

关键词：肝复乐胶囊原发性肝癌射频消融术治疗效果

HBeAg阳性慢性乙型肝炎病毒携带者中医证型与HBV DNA的关系

在线全文

学校读者我要写书评

暂无评论

南方医科大学学报 2012年第7期32卷 960-962页

作者：谢和平杨宏志吴伟康关卫兵柯千山李永伟戴敏肖阁敏李杨湄张炯善中山大学附属第三医院中医科广东广州510630

目的研究HBeAg阳性慢性乙型肝炎病毒(HBV)携带者的中医证型及病性与HBV DNA的关系。方法将185例HBeAg阳性慢性HBV携带者中医证型概括为单一证型(肝气郁结,肝肾亏虚,脾肾亏虚,湿热内蕴,瘀血阻络)、复合证型和无证可辨型。病性划分为实证... 详细信息

目的研究HBeAg阳性慢性乙型肝炎病毒(HBV)携带者的中医证型及病性与HBV DNA的关系。方法将185例HBeAg阳性慢性HBV携带者中医证型概括为单一证型(肝气郁结,肝肾亏虚,脾肾亏虚,湿热内蕴,瘀血阻络)、复合证型和无证可辨型。病性划分为实证、虚证及虚实夹杂证。同时检测其血清HBVDNA水平,并分析其与中医证型及病性的关系。结果无证可辨型、单一证型及复合证型之间HBV DNA无统计学差异(F=0.910,P=0.404)。单一证型之内的不同证型之间HBV DNA亦无统计学差异(χ2=4.672,P=0.323)。不同病性之间HBV DNA无统计学差异(F=0.631,P=0.596)。结论 HBV DNA不宜作为HBeAg阳性慢性HBV携带者中医证型的微观辨证指标。

关键词：乙型肝炎病毒携带者免疫耐受期中医证型

在线全文

学校读者我要写书评

暂无评论

STX6在肝细胞癌预后评估中的作用

新医学 2020年第6期51卷 482-488页

作者：廖扬静关卫兵张炯善肖阁敏杨宏志中山大学附属第三医院中医科广州510630

目的探讨突触融合蛋白6(STX6)表达水平与肝细胞癌(肝癌)患者临床病理参数的关系,评估STX6在肝癌预后评估中的价值。方法通过TCGA公共数据库获得371例肝癌组织和肝癌旁组织STX6的表达数据及临床资料,分析STX6在肝癌组织及肝癌旁组织中的... 详细信息

目的探讨突触融合蛋白6(STX6)表达水平与肝细胞癌(肝癌)患者临床病理参数的关系,评估STX6在肝癌预后评估中的价值。方法通过TCGA公共数据库获得371例肝癌组织和肝癌旁组织STX6的表达数据及临床资料,分析STX6在肝癌组织及肝癌旁组织中的表达差异及对肝癌患者的预后影响。使用实时定量PCR检测58例肝癌患者的新鲜冷冻肿瘤组织样本及肝癌旁组织的STX6 mRNA表达水平。采用蛋白免疫印迹法检测8例肝癌患者的肿瘤组织和肝癌旁组织、正常肝细胞LO2和7种人肝癌细胞系细胞STX6蛋白表达差异,免疫组织化学染色(免疫组化)法观察肝癌患者的肿瘤组织和肝癌旁组织STX6蛋白染色差异,根据STX6 mRNA表达水平分为STX6低表达组与STX6高表达组,分析肝癌患者STX6 mRNA表达与临床病理参数和肝癌生存预后的关系,并建立Cox回归模型判断STX6对肝癌患者预后的影响。结果TCGA数据库的基因芯片及临床数据分析显示,371例肝癌组织的STX6 mRNA表达水平高于肝癌旁组织(P<0.001),并且肝癌组织STX6 mRNA表达水平随肿瘤临床分期(Ⅰ~Ⅲ期)及病理分期(G1~G3期)升高而升高(总体及组间两两比较P均<0.05),STX6高表达组肝癌患者总生存率低于STX6低表达组(P<0.05)。58例肝癌组织中STX6 mRNA表达水平高于肝癌旁组织(P<0.05)。进一步分析显示,STX6高表达者的肿瘤分化程度较低、肿瘤较大、美国癌症联合委员会(AJCC)分期较高(P均<0.05)。蛋白免疫印迹显示,肝癌组织中STX6蛋白表达较肝癌旁组织升高(8例标本中有6例提示高表达)。7种不同肝癌细胞系细胞中的STX6蛋白表达均较人正常肝细胞升高。免疫组化也显示STX6在肝癌组织中的表达高于肝癌旁组织,并且主要在细胞质中表达。STX6高表达组肝癌患者的整体生存率低于低表达组(P=0.039)。Cox回归分析显示,AJCC肿瘤分期(HR=5.454,95%CI 1.825~16.297,P=0.002)和STX6 mRNA表达水平(HR=3.872,95%CI 1.641~9.140,P=0.002)与肝癌术后总生存率密切相关。结论STX6水平可以作为评估肝癌的预后分子标志物。

关键词：突触融合蛋白6 肝细胞癌预后